Home › Companies › MAIA

MAIA Biotechnology, Inc.

MAIA Lead: Phase 2 3 Biotech Distilled articles ↓

Oncology Small Molecule

Most recent annual filing: 2026-03-23

Pipeline (7 active programs)

ateganosine

6-thio-dG · 6-thio-2'-deoxyguanosine · THIO · THIO-104 · THIO-101

Small Molecule Target: telomere, telomerase

Non-Small Cell Lung Cancer Phase 2 BeOne Medicines

ateganosine

THIO · 6-thio-dG · 6-thio-2'-deoxyguanosine

Small Molecule Target: telomere, telomerase

Hepatocellular Carcinoma Phase 2 BeOne Medicines
Colorectal Cancer Phase 2 BeOne Medicines
Pediatric-Type Diffuse High-Grade Glioma Preclinical

MAIA-2021-20

Small Molecule Target: telomere, telomerase

Undisclosed indication Preclinical

MAIA-2022-12

Small Molecule Target: telomere, telomerase

Undisclosed indication Preclinical

MAIA-2021-029

Small Molecule Target: telomere, telomerase

Undisclosed indication Preclinical

Biotech Distilled coverage (3)

2026-05-15 UPDATE: MAIA Biotechnology (MAIA) - The Wainwright Divorce Is Final 🔒 Paid
2026-05-12 UPDATE: MAIA Biotechnology (MAIA) - The Banker Lawsuit Lands and a Bitcoin Plan Surfaces
2026-03-30 Maia Biotechnology (MAIA) - Scientific Deep Dive for Ateganosine and Pipeline Products 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.